Menu
Menu
Applied StemCell, Inc (ASC) utilizes three core gene editing technologies, TARGATT™, Sselect™, and AccuBase™, for cell engineering. These powerful tools allow ASC to safely and efficiently introduce complex and mainstream modifications in induced pluripotent stem cells (iPSCs), HEK293 cells, CHO cell, and animal models.
ASC has exclusive rights for TARGATT™ from Stanford University. Dr. Ruby Chen-Tsai, Ph.D., ASC’s President and CEO, and Dr. Alfonso Farruggio, Ph.D., Head of Research and Development, are co-inventors of the knock-in technology, TARGATT™. TARGATT™ enables large fragment insertion, up to 20kb, at a pre-selected locus. SSELECT Sselect™, an enhanced gene insertion method, uses our newly engineered enzyme that facilitates the site-specific, single-copy insertion of large DNA fragments (up to 20 kb). ASC holds full rights for SSELECT Sselect™.
ASC has the rights from Base Tx for the use of AccuBase™. AccuBase™ is a highly efficient technology that permits the editing of multiple target sites in a single cell with zero off-target events. It is ideal for point mutation projects and gene knock-out studies.
When you partner with ASC, you don’t have to worry about obtaining any additional licensing, and you will receive full support from the scientists who worked directly on developing the gene-editing system. Licensing and partnership opportunities are available for preclinical research, product development, and biotherapeutic development worldwide.
| Catalog ID# | Service Name | Price |
|---|---|---|